It is expected that, for clinical applications, it will be possible to select and administer an RRV that will be effective prior to the start of treatment by examining the expression levels of PiT-1 and PiT-2 receptors in a biopsy of the patient’s tumor as markers for personalized cancer virotherapy. The gene discussed is SLC20A2; the disease is neoplasm.